tbuckley/cabot-search huggingface dataset:
TOXICOLOGY AND MEDICAL JURISPRUDENCE.
Journal: JAMA (1883)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
1123-187 Soluble CD40 ligand in pulmonary arterial hypertension: Possible pathogenic role of interaction between platelets and endothelial cells
Authors: Jan K Damås, Kari Otterdal, Arne Yndestad, Halfdan Aass, Nils Olav Solum, Stig S Frøland, Svein Simonsen, Pål Aukrust, Arne K Andreassen
Journal: Journal of the American College of Cardiology (2004)
The presenile dementias
Authors: C. M. Poser
Journal: JAMA (1975)

A PROGRESSION of peculiarities that may be as harmless as the faux pas of the absent-minded professor or as tragic as the deterioration of King Lear forms the spectrum of what in its fully developed form is called dementia. Simply defined, it is intellectual disintegration. The manifestations of dementia vary considerably, reflecting the mental, social, and emotional resources of a person before his illness began. Unfortunately, it often strikes the individual at the height of his productivity. The first symptom of the condition may be a decrease in expected level of functioning, and thus the disease may be very closely tied to the patient's work or professional status. It is important to note that the symptoms that usher in the process of dementia differ little from those that occur in normal people who are exhausted, anxious, or under severe pressure. Thus, a frequent early complaint is that the patient is
State-Specific Prevalence of Cigarette Smoking— United States, 1995
Journal: JAMA (1996)

State-specific variation in the prevalence of cigarette smoking contributes to differences in the mortality patterns of smoking-related diseases, such as lung cancer, coronary heart disease, chronic bronchitis, and emphysema. In 1990, approximately 400,000 deaths were attributable to smoking: the median percentage of deaths attributable to smoking in all states were 19.2% (range: 13.4% in Utah to 24.0% in Nevada). State-specific surveillance of the prevalence of cigarette smoking can be used to direct and evaluate public health interventions to reduce smoking and the burden of smoking-related diseases on society. In June 1996, the Council of State and Territorial Epidemiologists (CSTE) recommended that cigarette smoking be added to the list of conditions designated as reportable by states to CDC. This report responds to the CSTE recommendation and summarizes state-specific prevalences of cigarette smoking by U.S. adults in 1995. During 1995, the prevalence of smoking varied among states and ranged from 13.2% (Utah) to 27.8% (Kentucky).
Impact of previous adjuvant oxaliplatin combination therapy on survival in elderly colorectal cancer patients with recurrence.
Authors: Yusuke Nagata, Katsushi Amano, Hayato Mikuni, Tomohiro Kano, Masashi Ishikawa, Utako Ishimoto, Takashi Nishimura, Masaaki Noguchi, Ryoichi Sawada, Tomonori Imakita, Masahisa Ohkuma, Hiroaki Aoki, Eijiro Nagasaki, Makoto Kosuge, Atsushi Hokari, Masaichi Ogawa, Ken Eto, Masayuki Saruta
Journal: Journal of Clinical Oncology (2022)

48 Background: The benefit of adjuvant chemotherapy with oxaliplatin for elderly patients with colorectal cancer (CRC) remains controversial. Our study could not demonstrate the benefit of adding oxaliplatin for elderly CRC patients aged over 70 years as with the previous clinical trials. Here, we evaluated the prognosis after recurrence in the elderly patients who received adjuvant chemotherapy. Methods: This retrospective study included patients aged over 70 years who were diagnosed with high-risk stage II and stage III CRC and received adjuvant chemotherapy in our two hospitals (The Jikei University Hospital and Katsushika Medical Center) between January 2010 and December 2019. The patients were divided into two groups; patients who received fluoropyrimidine monotherapy were included in Fp group and those who received fluoropyrimidine plus oxaliplatin were included in Fp+OX group. Moreover, we evaluated patient characteristics, treatment, and survival in the patients with recurrence and compared them between two groups. Results: A total of 127 patients received adjuvant chemotherapy; 75 patients in Fp group and 52 patients in Fp+OX group. With a median follow-up time of 64.5 months, the 5-years disease-free survival and 5-years overall survival in Fp group/Fp+OX group were 70.6/67.1% (hazard ratio [HR] 1.10, 95% confidence interval [CI] 0.61–1.98) and 89.0/71.8% (HR 1.48, 95% CI 0.76–2.88), respectively. The benefit of adding oxaliplatin was not observed. Among them, 15 patients in Fp group and 14 patients in Fp+OX group were relapsed; median age was 78 (range: 72-83) and 78 (range: 72-86) years, male was 67% and 64%, PS of 0/1 was 67/33% and 86/14%, primary tumor site of right/left was 47/53% and 57/43%, and RAS mutation was 20% and 29%, respectively. Median relapse-free survival was 17.7 and 14.3 months (p = 0.453). There were no significant differences in treatment after recurrence; aggressive treatment (surgery/chemotherapy) was 73% (33/40%) and 86% (21/65%), best supportive care was 7% each, and unknown was 20% and 7%, respectively. However, the median overall survival from the date of relapse was significantly worse in Fp+OX group than Fp group (45.0 and 14.4 months, p = 0.011). Conclusions: Recurrence after receiving adjuvant oxaliplatin combination therapy was considered as one of the poor prognostic factors. It might attenuate the benefit of adding oxaliplatin in adjuvant setting in elderly patients.
Candidate Role for Toll-like Receptor 3 L412F Polymorphism and Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Authors: Aoife N. McElroy, Rachele Invernizzi, Joanna W. Laskowska, Andrew O’Neill, Mohammad Doroudian, Mohsen Moghoofei, Shayan Mostafaei, Feng Li, Alexander A. Przybylski, David N. O’Dwyer, Andrew G. Bowie, Padraic G. Fallon, Toby M. Maher, Cory M. Hogaboam, Philip L. Molyneaux, Nik Hirani, Michelle E. Armstrong, Seamas C. Donnelly
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

Rationale: The Toll-like receptor 3 Leu412Phe (TLR3 L412F) polymorphism attenuates cellular antiviral responses and is associated with accelerated disease progression in idiopathic pulmonary fibrosis (IPF). The role of TLR3 L412F in bacterial infection in IPF or in acute exacerbations (AE) has not been reported. Objectives: To characterize the association between TLR3 L412F and AE-related death in IPF. To determine the effect of TLR3 L412F on the lung microbiome and on antibacterial TLR responses of primary lung fibroblasts from patients with IPF. Methods: TLR-mediated antibacterial and antiviral responses were quantitated in L412F wild-type and 412F-heterozygous primary lung fibroblasts from patients with IPF using ELISA, Western blot analysis, and quantitative PCR. Hierarchical heatmap analysis was employed to establish bacterial and viral clustering in nasopharyngeal lavage samples from patients with AE-IPF. 16S ribosomal RNA quantitative PCR and pyrosequencing were used to determine the effect of TLR3 L412F on the IPF lung microbiome. Measurements and Main Results: A significant increase in AE-related death in patients with 412F-variant IPF was reported. We established that 412F-heterozygous IPF lung fibroblasts have reduced antibacterial TLR responses to LPS (TLR4), Pam3CYSK4 (TLR1/2), flagellin (TLR5), and FSL-1 (TLR6/1) and have reduced responses to live Pseudomonas aeruginosa infection. Using 16S ribosomal RNA sequencing, we demonstrated that 412F-heterozygous patients with IPF have a dysregulated lung microbiome with increased frequencies of Streptococcus and Staphylococcus spp. Conclusions: This study reveals that TLR3 L412F dysregulates the IPF lung microbiome and reduces the responses of IPF lung fibroblasts to bacterial TLR agonists and live bacterial infection. These findings identify a candidate role for TLR3 L412F in viral- and bacterial-mediated AE death.
New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021
Authors: Eli S. Rosenberg, David R. Holtgrave, Vajeera Dorabawila, MaryBeth Conroy, Danielle Greene, Emily Lutterloh, Bryon Backenson, Dina Hoefer, Johanne Morne, Ursula Bauer, Howard A. Zucker
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Data from randomized clinical trials and real-world observational studies show that all three COVID-19 vaccines currently authorized for emergency use by the Food and Drug Administration* are safe and highly effective for preventing COVID-19-related serious illness, hospitalization, and death (1,2). Studies of vaccine effectiveness (VE) for preventing new infections and hospitalizations attributable to SARS-CoV-2, the virus that causes COVID-19), particularly as the B.1.617.2 (Delta) variant has become predominant, are limited in the United States (3). In this study, the New York State Department of Health linked statewide immunization, laboratory testing, and hospitalization databases for New York to estimate rates of new laboratory-confirmed COVID-19 cases and hospitalizations by vaccination status among adults, as well as corresponding VE for full vaccination in the population, across all three authorized vaccine products. During May 3-July 25, 2021, the overall age-adjusted VE against new COVID-19 cases for all adults declined from 91.8% to 75.0%. During the same period, the overall age-adjusted VE against hospitalization was relatively stable, ranging from 89.5% to 95.1%. Currently authorized vaccines have high effectiveness against COVID-19 hospitalization, but effectiveness against new cases appears to have declined in recent months, coinciding with the Delta variant's increase from <2% to >80% in the U.S. region that includes New York and relaxation of masking and physical distancing recommendations. To reduce new COVID-19 cases and hospitalizations, these findings support the implementation of a layered approach centered on vaccination, as well as other prevention strategies such as masking and physical distancing.
Angiogram Not Published
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Food production and safety
Journal: BMJ (1999)

Objectives To examine the adherence by senior NHS medical staff to the BMA guidelines on the ethical responsibilities of doctors towards themselves and their families.Design Postal semistructured questionnaire.Setting Four randomly selected NHS trusts and three local medical committees in South Thames region.Subjects Consultants and principals in general practice.Main outcome measures Personal use of health services. ResultsThe response rate was 64% (724) for general practitioners and 72% (427) for consultants after three mailings.Most (1106, 96%) respondents were registered with a general practitioner, although little use was made of their services.159 (26%) general practitioners were registered with a general practitioner in their own practice and 80 (11%) admitted to looking after members of their family.73 (24%) consultants would never see their general practitioner before obtaining consultant advice.Most consultants and general practitioners admitted to prescribing for themselves and their family.Responses to vignettes for different health problems indicated a general reluctance to take time off, but there were differences between consultants and general practitioners and by sex.Views on improvements needed included the possibility of a "doctor's doctor," access to out of area secondary care, an occupational health service for general practitioners, and regular health check ups. ConclusionThe guidelines are largely not being followed, perhaps because of the difficulties of obtaining access to general practitioners outside working hours.The occupational health service should be expanded and a general practitioner service for NHS staff piloted.
TCT-350 Drug-Eluting Stents for the Treatment of Very Long Coronary Artery Stenosis with Diabetes Mellitus: A Comparison with Sirolimus, Paclitaxel, Zotarolimus (Endeavor Resolute), BiolimusA9, EPC Capture and Everolimus-Eluting Stent: Multicenter Registry in Asia
Authors: Sunao Nakamura, Shotoro Nakamura, Hisao Ogawa, Jang-Ho Bae, Yeo Cahyadi, Wasan Udayachalerm, Damras Tresukosol, Sudaratana Tansuphaswadikul
Journal: Journal of the American College of Cardiology (2012)
Instructions to Authors
Journal: Cardiovascular Research (2001)

Cardiovascular Research is the International Basic Science Journal of the regular paper, but add (Abstract) at end.If the bibliography contains more European Society of Cardiology.The Journal is concerned with both than six authors, et al. should be added following the third author.basic and clinical research in the field of cardiovascular physiology and (10) Figures / Tables.Figures should be original laser prints or very pathophysiology.The Journal welcomes submission of papers both at the sharp, well-contrasting prints on glossy paper, suitable for immediate molecular, subcellular, cellular, organ and organism level and of clinically reproduction.Half-tone figures should be in black-and-white, very sharp, oriented papers offering insight into (patho)physiological mechanisms.well-contrasting, and on glossy paper.Any lettering in the figures should Manuscripts may be submitted as Regular Papers or as Letters to the be large enough to stand photographic reduction.Contributors should Editor.Moreover the Journal publishes Reviews and Editorials.Manu-prepare their figures for either one column width (84 mm) or the entire scripts are normally evaluated by three members from an international page width (175 mm).The maximum height is 240
Steroids, San Francisco
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Epilepsy induced by cardiac pacemaker
Authors: G. K. Danielson
Journal: JAMA (1967)

FOR MANY YEARS it has been recognized that specific sensory stimuli can precipitate convulsive attacks in susceptible individuals. Such reflex or sensory precipitated epilepsy (SPE) is uncommon and is found in only 5% to 7% of patients with epilepsy.<sup>1,2</sup>The following communication describes an unusual type of SPE in which seizures were initiated by the periodic discharge of an implanted cardiac pacemaker. To our knowledge, this is the first reported case of pacemaker-induced epilepsy. <h3>Report of a Case</h3> A 72-year-old white woman was admitted to the University of Kentucky Hospital on Nov 25, 1964, with a history of seizures which had begun three days prior to admission. The attacks occurred several times a day and were accompanied by tonic and clonic contractions, tongue biting, and unconsciousness. They were preceded by an aura of bright lights and noises and left the patient feeling dizzy and tired. Although she reported frequent
Covid-19: Vaccination during pregnancy is safe, finds large US study
Authors: Janice Hopkins Tanne
Journal: BMJ (2022)

A US study of 46 079 pregnancies has found that vaccination against covid-19 was safe and did not increase the risk of preterm birth or small for gestational age babies. 1 Pregnant women and those planning to get pregnant are included in vaccination programmes worldwide, but hesitancy has been widely reported because of concerns about vaccine safety.Unvaccinated pregnant women who get symptomatic covid-19 have a 70% risk of death compared with non-pregnant women with symptomatic infections, according to the researchers of the latest study from Yale University.They face more than double the risk of needing admission to an intensive care unit, intensive ventilation, and extracorporeal membrane oxygenation.This retrospective cohort study is a collaboration between the Centers for Disease Control and Prevention and eight Vaccine Safety Datalink healthcare organisations that represent about 3% of the US population.It followed a group of women aged 16-49 who had an estimated start of pregnancy between May and October 2020 and expected delivery dates of February to July 2021. 1
Retraction: Increased Levels of COX-2 and Prostaglandin E2 Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women
Authors: Kotha Subbaramaiah, Patrick G. Morris, Xi Kathy Zhou, Monica Morrow, Baoheng Du, Dilip Giri, Levy Kopelovich, Clifford A. Hudis, Andrew J. Dannenberg
Journal: Cancer Discovery (2021)
Obituary Listing
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
JAPAN
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Early perforation in appendicitis after age 60
Authors: A. G. Coran
Journal: JAMA (1966)

Twenty-eight consecutive cases of acute appendicitis have been reviewed in patients 60 to 91 years of age. The clinical picture was usually similar but less striking than that seen in young adults. The appendix had perforated in 17 of 21 patients operated upon more than 24 hours after onset of symptoms, but in only one of six patients operated upon before this time. Perforation was frequently correlated with septic complications and was felt to be the chief cause of mortality (2/28, 7%) and complication rate (11/28, 41%). Because of the high incidence of early perforation with acute appendicitis in the elderly, prompt surgical exploration is even more urgent than in younger patients.
Failure of Penicillin to Alter Acute Rheumatic Valvulitis
Authors: Vaisman B. Samuel
Journal: JAMA (1965)

A controlled study of the effects of penicillin on 165 patients with acute rheumatic fever has failed to demonstrate any alteration, attributable to the antibiotic, in valvular sequelae. The results suggest that the Streptococcus in the bacterial form does not play a continuing role in an acute episode of rheumatic fever once rheumatic symptoms have appeared.